S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
Google says its AI image-generator would sometimes 'overcompensate' for diversity
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
Google says its AI image-generator would sometimes 'overcompensate' for diversity
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
Google says its AI image-generator would sometimes 'overcompensate' for diversity
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
White House, tribal leaders hail 'historic' deal to restore salmon runs in Pacific Northwest
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
Google says its AI image-generator would sometimes 'overcompensate' for diversity
NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

$13.05
-0.45 (-3.33%)
(As of 02/23/2024 ET)
Today's Range
$13.05
$13.50
50-Day Range
$13.05
$17.50
52-Week Range
$8.98
$24.20
Volume
698 shs
Average Volume
2,654 shs
Market Capitalization
$16.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ACOR stock logo

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

ACOR Stock Price History

ACOR Stock News Headlines

Strange change at your bank
At least 41 major US banks have just made a drastic change to the way money in America works. It could have some major implications for you, your money and your retirement. But it’s crucial you understand what’s happening, before these changes get applied to your bank account.
Acorda: No policy vs. TikTok use in PNP
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
3 Biotech Stocks to Keep an Eye on in 2024
Acorda eyes Pinoy apps vs cybercrimes
Acorda Therapeutics Inc ACOR
3 Biotech Stocks Flashing Year-End 'Buy' Signals"
3 Safe Biotech Stocks to Buy This Week
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/24/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACOR
CUSIP
00484M10
Employees
111
Year Founded
1995

Profitability

Net Income
$-65,920,000.00
Pretax Margin
-16.72%

Debt

Sales & Book Value

Annual Sales
$118.57 million
Book Value
$77.13 per share

Miscellaneous

Free Float
1,210,000
Market Cap
$16.18 million
Optionable
Optionable
Beta
1.44

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Ron Cohen M.D. (Age 68)
    Founder, CEO, President & Director
    Comp: $984.15k
  • Mr. Michael A. Gesser M.B.A. (Age 61)
    Chief Financial Officer
    Comp: $459.15k
  • Mr. Kerry M. Clem (Age 54)
    Chief Commercial Officer
    Comp: $592.23k
  • Mr. Robert Morales (Age 56)
    Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller
  • Ms. Felicia Vonella
    Vice President of Investor Relations
  • Mr. Neil S. Belloff Esq. (Age 64)
    General Counsel & Corporate Secretary
  • Ms. Tierney Saccavino
    Executive Vice President of Corporate Communications
  • Ms. Denise J. Duca
    Executive Vice President of Human Resources
  • Mr. Andrew Mayer J.D.
    Senior Vice President
  • Sofia Ali
    Senior VP of Operations & Strategic Planning














ACOR Stock Analysis - Frequently Asked Questions

How have ACOR shares performed in 2024?

Acorda Therapeutics' stock was trading at $15.09 at the beginning of the year. Since then, ACOR stock has decreased by 13.5% and is now trading at $13.0461.
View the best growth stocks for 2024 here
.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 10,700 shares, a decrease of 12.3% from the January 15th total of 12,200 shares. Based on an average daily trading volume, of 4,200 shares, the short-interest ratio is presently 2.5 days. Approximately 0.9% of the company's shares are short sold.
View Acorda Therapeutics' Short Interest
.

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ACOR earnings forecast
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) EPS for the quarter, topping the consensus estimate of ($31.20) by $2.60. The biopharmaceutical company earned $31.46 million during the quarter, compared to analyst estimates of $30.57 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 21.45% and a negative net margin of 14.35%.

When did Acorda Therapeutics' stock split?

Acorda Therapeutics shares reverse split before market open on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACOR) was last updated on 2/24/2024 by MarketBeat.com Staff